

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2012/135790 A1

(43) International Publication Date

4 October 2012 (04.10.2012)

(51) International Patent Classification:

C08K 5/00 (2006.01) *C08K 5/24* (2006.01)
C08L 27/12 (2006.01) *C08K 5/405* (2006.01)
C08L 27/18 (2006.01)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2012/031734

(22) International Filing Date:

30 March 2012 (30.03.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/469,856 31 March 2011 (31.03.2011) US

(71) Applicant (for all designated States except US): **E. I. DU PONT DE NEMOURS AND COMPANY** [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BISH, Christopher, John** [GB/US]; 112 Quail Lane, Kennett Square, PA 19348 (US). **MORKEN, Peter, A.** [US/US]; 6 Weilers Bend, Wilmington, DE 19810 (US). **WHELAND, Robert, Clayton** [US/US]; 510 Twaddell Mill Road, Wilmington, DE 19807 (US).

(74) Agent: **KIRVAN, George, E.**; E. I. Du Pont De Nemours And Company, Legal Patent Records Center, 4417 Lancaster Pike, Wilmington, DE 19805 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))



WO 2012/135790 A1

(54) Title: CURABLE FLUOROELASTOMER COMPOSITION

(57) Abstract: Fluoroelastomer compositions comprising fluoroelastomers having copolymerized units of a nitrile-containing cure site monomer are cured with certain hydrazide curatives. The hydrazide is of the general formula $R^1(C(O))_nNHNHR^2$, wherein n is 1 or 2; R^1 is NH_2 , $NHNH_2$, NHR^3 , NR^3_2 , $NHNHC(O)NH_2$, $NHNHC(O)NHNH_2$, $NHNHR^2$, or $NHC(O)NHNH_2$; R^2 is H, alkyl, aryl, heterocycle, CO_2R^3 , $C(O)R^3$, CH_2R^4 , or $C(O)R^4$; R^3 is alkyl, aryl, heterocycle, or CH_2R^4 ; and R^4 is a fluoroalkyl group.

TITLE OF INVENTION
CURABLE FLUOROELASTOMER COMPOSITION

FIELD OF THE INVENTION

5 This invention relates to curable fluoroelastomer compositions and more particularly to fluoroelastomer compositions containing certain hydrazides as curing agents.

BACKGROUND OF THE INVENTION

Fluoroelastomers have achieved outstanding commercial success
10 and are used in a wide variety of applications in which severe environments are encountered, in particular those end uses where exposure to high temperatures and aggressive chemicals occurs. For example, these polymers are often used in seals for aircraft engines, in oil-well drilling devices, and in sealing elements for industrial equipment that
15 operates at high temperatures.

The outstanding properties of fluoroelastomers are largely attributable to the stability and inertness of the copolymerized fluorinated monomer units that make up the major portion of the polymer backbones in these compositions. Such monomers include vinylidene fluoride,
20 hexafluoropropylene, tetrafluoroethylene and perfluoro(alkyl vinyl) ethers. In order to develop elastomeric properties fully, fluoroelastomers are typically crosslinked, i.e. vulcanized. To this end, a small percentage of cure site monomer is copolymerized with the fluorinated monomer units. Cure site monomers containing at least one nitrile group, for example
25 perfluoro-8-cyano-5-methyl-3,6-dioxa-1-octene, are especially preferred. Such compositions are described in U.S. Patents 4,281,092; 4,394,489; 5,789,489; 5,789,509 and in WO 2011084404.

Bisamidoximes (U.S. Patent 5,668,221) and bisamidrazones (U.S. Patents 5,605,973; 5,637,648) have been used as vulcanizing agents for
30 fluoroelastomers having nitrile group cure sites. These cures may be scorchy, i.e. crosslinking may begin before the final shaping of the

composition. Also, the curatives require complex, multistep syntheses from expensive starting materials.

Other nitrogen containing nucleophilic compounds have been 5 employed to crosslink fluoroelastomers having nitrile group cure sites (U.S. Patent 6,638,999 B2). Some of these curatives are scorchy while others are volatile at rubber milling temperatures.

Fluoropolymers having pendant amidrazone or amidoxime groups are also known (U.S. Patent 7,300,985 B2). These polymers require an 10 additional polymer modification step in order to form crosslinks.

SUMMARY OF THE INVENTION

The present invention is directed to curable fluoroelastomer compositions which comprise a fluoroelastomer having nitrile group cure 15 sites and certain hydrazide as curatives. More specifically, the present invention is directed to a curable composition comprising:

- A) a fluoroelastomer comprising copolymerized units of a nitrile group-containing cure site monomer; and
- B) a hydrazide of the general formula $R^1(C(O))_nNHNHR^2$, wherein 20 n is 1 or 2; R^1 is NH_2 , $NHNH_2$, NHR^3 , NR^3_2 , $NHNHC(O)NH_2$, $NHNHC(O)NHNH_2$, $NHNHR_2$, or $NHC(O)NHNH_2$; R^2 is H, alkyl, aryl, heterocycle, CO_2R^3 , $C(O)R^3$, CH_2R^4 , or $C(O)R^4$; R^3 is alkyl, aryl, heterocycle, or CH_2R^4 ; and R^4 is a fluoroalkyl group.

Another aspect of the present invention is a cured article made from 25 the above composition.

DETAILED DESCRIPTION OF THE INVENTION

The fluoroelastomer that may be employed in the composition of the invention may be partially fluorinated or perfluorinated.

30 Fluoroelastomers preferably contain between 25 and 70 weight percent, based on the total weight of the fluoroelastomer, of copolymerized units of a first monomer which may be vinylidene fluoride (VF_2) or

tetrafluoroethylene (TFE). The remaining units in the fluoroelastomers are comprised of one or more additional copolymerized monomers, different from said first monomer, selected from the group consisting of

5 fluoromonomers, hydrocarbon olefins and mixtures thereof.

Fluoromonomers include fluorine-containing olefins and fluorine-containing vinyl ethers.

Fluorine-containing olefins which may be employed to make fluoroelastomers include, but are not limited to vinylidene fluoride (VF₂),

10 hexafluoropropylene (HFP), tetrafluoroethylene (TFE), 1,2,3,3,3-pentafluoropropene (1-HPFP), 1,1,3,3,3-pentafluoropropene (2-HPFP), chlorotrifluoroethylene (CTFE) and vinyl fluoride.

Fluorine-containing vinyl ethers that may be employed to make fluoroelastomers include, but are not limited to perfluoro(alkyl vinyl) ethers.

15 Perfluoro(alkyl vinyl) ethers (PAVE) suitable for use as monomers include those of the formula

$$CF_2=CFO(R_fO)_n(R_fO)_mR_f \quad (I)$$

where R_f and R_{f'} are different linear or branched perfluoroalkylene groups of 2-6 carbon atoms, m and n are independently 0-10, and R_f is a

20 perfluoroalkyl group of 1-6 carbon atoms.

A preferred class of perfluoro(alkyl vinyl) ethers includes compositions of the formula

$$CF_2=CFO(CF₂CFXO)_nR_f \quad (II)$$

where X is F or CF₃, n is 0-5, and R_f is a perfluoroalkyl group of 1-6

25 carbon atoms.

A most preferred class of perfluoro(alkyl vinyl) ethers includes those ethers wherein n is 0 or 1 and R_f contains 1-3 carbon atoms. Examples of such perfluorinated ethers include perfluoro(methyl vinyl ether) (PMVE), perfluoro(ethyl vinyl ether) (PEVE) and perfluoro(propyl vinyl ether)

30 (PPVE). Other useful monomers include those of the formula

$$CF_2=CFO[(CF_2)_mCF_2CFZO]_nR_f \quad (III)$$

where R_f is a perfluoroalkyl group having 1-6 carbon atoms,


$m = 0$ or 1 , $n = 0$ - 5 , and $Z = F$ or CF_3 . Preferred members of this class are those in which R_f is C_3F_7 , $m = 0$, and $n = 1$.

Additional perfluoro(alkyl vinyl) ether monomers include compounds 5 of the formula



where m and n independently = 0 - 10 , $p = 0$ - 3 , and $x = 1$ - 5 . Preferred members of this class include compounds where $n = 0$ - 1 , $m = 0$ - 1 , and $x = 1$.

10 Other examples of useful perfluoro(alkyl vinyl ethers) include



where $n = 1$ - 5 , $m = 1$ - 3 , and where, preferably, $n = 1$.


If copolymerized units of PAVE are present in fluoroelastomers employed in the invention, the PAVE content generally ranges from 25 to 15 75 weight percent, based on the total weight of the fluoroelastomer. If perfluoro(methyl vinyl ether) is used, then the fluoroelastomer preferably contains between 30 and 65 wt.% copolymerized PMVE units.

Hydrocarbon olefins useful in the fluoroelastomers employed in the invention include, but are not limited to ethylene and propylene. If 20 copolymerized units of a hydrocarbon olefin are present in the fluoroelastomers, hydrocarbon olefin content is generally 4 to 30 weight percent.


The fluoroelastomer further contains copolymerized units of at least one cure site monomer, generally in amounts of from 0.1-5 mole percent. 25 The range is preferably between 0.3-1.5 mole percent. Although more than one type of cure site monomer may be present, most commonly one cure site monomer is used and it contains at least one nitrile substituent group. Suitable cure site monomers include nitrile-containing fluorinated olefins and nitrile-containing fluorinated vinyl ethers. Useful nitrile-containing cure site monomers include those of the formulas shown below.




where $n = 2$ - 12 , preferably 2-6;



where n= 0-4, preferably 0-2;




5 where x = 1-2, and n = 1-4; and



where n = 2-4.

Those of formula (VIII) are preferred. Especially preferred cure site monomers are perfluorinated polyethers having a nitrile group and a 10 trifluorovinyl ether group. A most preferred cure site monomer is



i.e. perfluoro(8-cyano-5-methyl-3,6-dioxa-1-octene) or 8-CNVE.

A first aspect of this invention is a curable composition comprising

- A) a fluoroelastomer comprising copolymerized units of a cure site monomer selected from the group consisting of nitrile-containing fluorinated olefins and nitrile-containing fluorinated vinyl ethers; and B) a certain hydrazide. The hydrazide may be a mono-, di-, or poly-hydrazide. The hydrazide is of the general formula $\text{R}^1(\text{C(O)})_n\text{NHNHR}^2$, wherein n is 1 or 2; R^1 is NH_2 , NHNH_2 , NHR^3 , NR^3_2 , NHNHC(O)NH_2 , NHNHC(O)NHNH_2 , 15 NHNHR^2 , or NHC(O)NHNH_2 ; R^2 is H, alkyl, aryl, heterocycle, CO_2R^3 , C(O)R^3 , CH_2R^4 , or C(O)R^4 ; R^3 is alkyl, aryl, heterocycle, or CH_2R^4 ; and 20 R^4 is a fluoroalkyl group. The alkyl, aryl, benzyl or heterocycle groups may contain additional functional groups such as, but not limited to halogen, ether, or amide groups. The fluoroalkyl group has at least one of the 25 hydrogen atoms replaced by fluorine and may optionally contain 1 or more oxygen atoms in the chain. R^2 , R^3 , or R^4 may have 1, 2, or more points of attachment to a hydrazide to afford mono-, di-, or poly-hydrazide. Compounds that decompose to form one of these hydrazides may also be 30 employed in the composition of the invention. The hydrazide may also be a salt, e.g. semicarbazide hydrochloride. Lastly, the oxygen atom may be replaced by sulfur.

Preferred hydrazides include those wherein n is 1; R¹ is NH₂, NHNH₂, NHR³, NR³₂, NHNHC(O)NH₂, NHNHC(O)NHNH₂, NHNHR², or NHC(O)NHNH₂; and R² is H; n is 2; R¹ is NH₂, NHNH₂, NHR³, NR³₂, NHNHC(O)NH₂, NHNHR², or NHC(O)NHNH₂; and R² is H; n is 1; R¹ is NH₂, NHNH₂, NHR³, NR³₂, NHNHC(O)NH₂, NHNHC(O)NHNH₂, NHNHR², or NHC(O)NHNH₂; and R² is CO₂R³; and n is 2; R¹ is NH₂, NHNH₂, NHR³, NR³₂, NHNHC(O)NH₂, NHNHC(O)NHNH₂, NHNHR², or NHC(O)NHNH₂; and R² is CO₂R³.

10 Specific examples of these hydrazide curatives include, but are not limited to carbohydrazide; carbonic dihydrazide, dihydrochloride; 4-phenylsemicarbazide; 4-phenylsemicarbazide hydrochloride; 4,4-diphenylsemicarbazide; oxamic hydrazide; oxalyldihydrazide; semicarbazide; 1,2-hydrazinedicarboxylic acid, dihydrazide; 15 diaminobiuret; thiocarbohydrazide; and thiosemicarbazide. An example of a dihydrazide is p-phenylenebissemicarbazide. More preferred hydrazides include carbohydrazide; 4-phenylsemicarbazide; oxamic hydrazide; semicarbazide, and oxalyldihydrazide.

It is theorized that these hydrazides act as curing agents by causing 20 the dimerization of polymer chain bound nitrile groups to form 1,2,4-triazole rings, thus crosslinking the fluoroelastomer. The hydrazides are less volatile than curatives such as hydrazine or t-butyl carbamate, making the hydrazide curatives less likely to be fugitive during mixing and shaping processes.

25 In order to be useful as either the major, or as the only curative for these fluoroelastomers, the level of hydrazide should be about 0.05 to 7 parts hydrazide per 100 parts fluoroelastomer, preferably about 0.1 to 3 parts hydrazide per 100 parts fluoroelastomer, most preferably about 0.5 to 2 parts hydrazide per 100 parts fluoroelastomer. As used herein, 30 "parts" refers to parts by weight, unless otherwise indicated.

An appropriate level of hydrazide can be selected by considering cure properties, for example the time to develop maximum moving die

rheometer (MDR) torque and minimum Mooney scorch of the curable compositions. The optimum level will depend on the particular combination of fluoroelastomer and hydrazide.

5 Optionally, a curative accelerator, e.g. a compound that releases ammonia at curing temperatures, may be used in combination with a hydrazide curative. Examples of compounds that decompose to release ammonia at curing temperatures include those disclosed in U.S. 6,281,296 B1 and U.S. 2011/0009569.

10 Optionally, another curative commonly employed to crosslink fluoroelastomers having nitrile-group cure sites may be used in addition to the hydrazide. Examples of such other curatives include, but are not limited to diaminobisphenol AF, 2,2-bis(3-amino-4-anilinophenyl)hexafluoropropane, mono- or bis-amidines, mono- or bis-15 amidrazone, mono- or bis-amidoximes, or an organic peroxide plus coagent.

20 Additives, such as carbon black, fluoropolymer micropowders, stabilizers, plasticizers, lubricants, fillers, and processing aids typically utilized in fluoroelastomer compounding can be incorporated into the compositions of the present invention, provided they have adequate stability for the intended service conditions.

25 The curable compositions of the invention may be prepared by mixing the fluoroelastomer, hydrazide and other components using standard rubber compounding procedures. For example, the components may be mixed on a two roll rubber mill, in an internal mixer (e.g. a Banbury® internal mixer), or in an extruder. The curable compositions may then be crosslinked (i.e. cured) by application of heat and/or pressure. When compression molding is utilized, a press cure cycle is generally followed by a post cure cycle during which the press cured 30 composition is heated at elevated temperatures in excess of 300°C for several hours.

The curable compositions of the present invention are useful in production of gaskets, tubing, and seals. Such cured articles are generally produced by molding a compounded formulation of the curable

5 composition with various additives under pressure, curing the part, and then subjecting it to a post cure cycle. The cured compositions have excellent thermal stability, steam and chemical resistance. Volume swell (ASTM D1414) after exposure to 225°C water for at least 168 hours, preferably at least 336 hours, is less than 5%. Also compression set,

10 300°C, 70 hours, 15% compression (ASTM D395) is less than 70%. The cured compositions are particularly useful in applications such as seals and gaskets for manufacturing semiconductor devices, and in seals for high temperature automotive uses.

Other fluoropolymers containing nitrile cure sites, such as

15 fluoroplastics may be substituted for fluoroelastomers in the compositions of the invention.

The invention is now illustrated by certain embodiments wherein all parts are by weight unless otherwise specified.

20

EXAMPLES
TEST METHODS

Cure Characteristics

Cure characteristics were measured using a Monsanto MDR 2000 instrument under the following conditions:

25

Moving die frequency: 1.66 Hz

Oscillation amplitude: ± 0.5 degrees

Temperature: 190°C, unless otherwise noted

Sample size: Disks having diameter of 1.5 inches (38 mm)

Duration of test: 30 minutes

30

The following cure parameters were recorded:

M_H : maximum torque level, in units of dN·m

M_L : minimum torque level, in units of dN·m

Tc90: time to 90% of maximum torque, minutes

5 Test specimens were prepared from elastomer compounded with appropriate additives, as described in the formulations listed in the Examples below. Compounding was carried out on a rubber mill. The milled composition was formed into a sheet and a 10 g sample was die cut into a disk to form the test specimen.

10 Compression set of O-ring samples was determined in accordance with ASTM D395. Mean values are reported.

15 Volume swell in water was measured at 225°C for the time indicated in the Tables in accordance with ASTM D1414.

The following fluoroelastomer polymers were used in the Examples:
FFKM - A terpolymer containing 61.8 mole percent units of TFE, 37.4 mole percent units of PMVE and 0.80 mole percent units of 8-CNVE was
20 prepared according to the general process described in U.S. Patent No. 5,789,489.

FKM - A terpolymer containing 23.3 mole percent units of TFE, 50.7 mole percent units of VF₂, 25.1 mole percent units of hexafluoropropylene and 0.90 mole percent units of 8-CNVE.

25 Examples 1-2
Curable compositions of the invention were compounded on a two-roll rubber mill in the proportions shown in Table I. The compounded compositions are labeled Example 1 (4-phenylsemicarbazide, available from Alfa-Aesar) and Example 2 (carbohydrazide, available from Sigma-Aldrich) in Table I. Cure characteristics of the compounded compositions are also shown in Table I. O-rings were made by press curing the curable

compositions at a temperature of 190°C for Tc90 plus 5 minutes, followed by a post cure in a nitrogen atmosphere at a temperature of 305°C for 26 hours after a slow temperature ramp up from room temperature.

5 Compression set and volume swell values are also shown in Table I.

In order to compare volume swells of the compositions of the invention with a prior art composition, o-rings were made from a similar compound, but containing 0.25 phr urea as curative, rather than a hydrazide curative. After only 168 hours of exposure to 225°C water, the
10 urea cured o-rings exhibited a 15.7 % volume swell.

TABLE I

<u>Formulation</u> <u>(phr¹)</u>	<u>Example 1</u>	<u>Example 2</u>
FFKM	100	100
Carbon Black MT N990	30	30
4-phenyl- semicarbazide	1.14	0
Carbohydrazide	0	0.68
<u>Cure</u> <u>Characteristics</u>		
M _L (dN·m)	1.97	3.23
M _H (dN·m)	14.06	17.07
Tc90, minutes	16.5	18.5
Compression set, 300°C, 70 hours, 15% compression, %	41.3	27.0
Volume swell, 336 hours, %	0.6	1.2

¹Parts by weight per hundred parts by weight fluoroelastomer

5 Examples 3-5

Curable compositions of the invention were compounded on a two-roll rubber mill in the proportions shown in Table II. The compounded compositions are labeled Example 3 (oxamic hydrazide, available from Acros Organics), Example 4 (oxalyl dihydrazide, available from Sigma-Aldrich) and Example 5 (semicarbazide, prepared from urea and hydrazine hydrate according to the general procedure in Example 1 of U.S. 4,482,738, except hydrogen chloride was omitted) in Table II. Cure characteristics of the compounded compositions are also shown in Table II.

TABLE II

<u>Formulation (phr)</u>	<u>Example 3</u>	<u>Example 4</u>	<u>Example 5</u>
FFKM	100	100	100
Carbon Black MT N990	30	30	30
Oxamic hydrazide	0.78	0	0
Oxalyl dihydrazide	0	0.89	0
Semicarbazide	0	0	0.57
<u>Cure Characteristics</u>			
M _L (dN·m)	2.38	2.95	3.55
M _H (dN·m)	17.30	18.03	18.74
Tc90, minutes	12.8	18.3	9.0
<u>Compression set, 300°C, 70 hours, 15% compression, %</u>	33.3	25.4	25.4
<u>Volume swell, 168 hours, %</u>	1.6	1.2	0.5

Examples 6-8

5 Curable compositions of the invention were compounded on a two-roll rubber mill in the proportions shown in Table III. The compounded compositions are labeled Example 6 (4-phenylsemicarbazide hydrochloride, available from Sigma-Aldrich), Example 7 (4,4-diphenylsemicarbazide, prepared from diphenylcarbamoyl chloride and 10 anhydrous hydrazine) and Example 8 (semicarbazide hydrochloride, available from Sigma-Aldrich) in Table III. Cure characteristics of the compounded compositions are also shown in Table III.

TABLE III

<u>Formulation (phr)</u>	<u>Example 6</u>	<u>Example 7</u>	<u>Example 8</u>
FFKM	100	100	100
Carbon Black MT N990	30	30	30
4-phenyl- semicarbazide hydrochloride	1.42	0	0
4,4- diphenylsemicarbazide	0	1.72	0
Semicarbazide hydrochloride	0	0	0.84
<u>Cure Characteristics</u>			
M _L (dN·m)	1.75	1.71	2.22
M _H (dN·m)	6.69	3.04	6.01
T _c 90, minutes	26.8	26.0	27.0
<u>Compression set</u> , 300°C, 70 hours, 15% compression, %	47.6	44.4	36.5
<u>Volume swell</u> , 168 hours, %	1.7	2.0	2.0

5 Example 9

A curable composition of the invention was compounded on a two-roll rubber mill in the proportions shown in Table IV. The compounded composition is labeled Example 9 (carbohydrazide) in Table IV. Cure characteristics (at 199°C) of the compounded compositions are also 10 shown in Table IV. O-rings were made by press curing the curable

composition at a temperature of 199°C for Tc90 plus 5 minutes, followed by a post cure in a nitrogen atmosphere at a temperature of 260°C for 8 hours after a slow temperature ramp up from room temperature.

5 Compression set is also shown in Table IV.

TABLE IV

<u>Formulation (phr)</u>	<u>Example 9</u>
FKM	100
Carbon Black MT N990	30
Carbohydrazide	1.0
<u>Cure Characteristics</u>	
M _L (dN·m)	5.62
M _H (dN·m)	15.93
Tc90, minutes	19.2
<u>Compression set,</u> 200°C, 70 hours, 25% compression, %	18

CLAIMS

5 **What is Claimed is:**

1. A curable composition comprising:
 - A) a fluoroelastomer comprising copolymerized units of a nitrile group-containing cure site monomer; and
 - B) a hydrazide of the general formula $R^1(C(O))_nNHNHR^2$, wherein n is 1 or 2; R^1 is NH_2 , NHH_2 , NHR^3 , NR^3_2 , $NHNHC(O)NH_2$, $NHNHC(O)NHNH_2$, $NHNHR^2$, or $NHC(O)NHNH_2$; R^2 is H, alkyl, aryl, heterocycle, CO_2R^3 , $C(O)R^3$, CH_2R^4 or $C(O)R^4$; R^3 is alkyl, aryl, heterocycle, or CH_2R^4 ; and R^4 is a fluoroalkyl group.
2. A curable composition of claim 1 wherein n is 1; R^1 is NH_2 , NHH_2 , NHR^3 , NR^3_2 , $NHNHC(O)NH_2$, $NHNHC(O)NHNH_2$, $NHNHR^2$, or $NHC(O)NHNH_2$; and R^2 is H.
3. A curable composition of claim 1 wherein n is 2; R^1 is NH_2 , NHH_2 , NHR^3 , NR^3_2 , $NHNHC(O)NH_2$, $NHNHC(O)NHNH_2$, $NHNHR^2$, or $NHC(O)NHNH_2$; and R^2 is H.
4. A curable composition of claim 1 wherein n is 1; R^1 is NH_2 , NHH_2 , NHR^3 , NR^3_2 , $NHNHC(O)NH_2$, $NHNHC(O)NHNH_2$, $NHNHR^2$, or $NHC(O)NHNH_2$; and R^2 is CO_2R^3 .
5. A curable composition of claim 1 wherein n is 2; R^1 is NH_2 , NHH_2 , NHR^3 , NR^3_2 , $NHNHC(O)NH_2$, $NHNHC(O)NHNH_2$, $NHNHR^2$, or $NHC(O)NHNH_2$; and R^2 is CO_2R^3 .
6. A curable composition of claim 1 wherein said hydrazide is selected from the group consisting of carbohydrazide; carbonic dihydrazide, dihydrochloride; 4-phenylsemicarbazide; 4-phenylsemicarbazide hydrochloride; 4,4-diphenylsemicarbazide; oxamic hydrazide; oxalyldihydrazide; semicarbazide; 1,2-hydrazinedicarboxylic acid, dihydrazide; diaminobiuret; thiocarbohydrazide; and thiosemicarbazide.

7. A curable composition of claim 1 wherein said hydrazide has at least one oxygen atom replaced by a sulfur atom.
8. A curable composition of claim 1 further comprising a curative 5 accelerator.
9. A cured article made from the composition of claim 1.
10. A cured article of claim 9 having a volume swell, measured according to ASTM D1414, after exposure to 225°C water for at least 168 hours of less than 5% and a compression set, 300°C, 70 hours, 15% 10 compression, measured according to ASTM D395, of less than 70%.

INTERNATIONAL SEARCH REPORT

International application No PCT/US2012/031734

A. CLASSIFICATION OF SUBJECT MATTER INV. C08K5/00 C08L27/12 C08L27/18 C08K5/24 C08K5/405 ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C08K C08L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/59005 A2 (DUPONT DOW ELASTOMERS LLC [US]) 16 August 2001 (2001-08-16) example 3 claim 5 ----- A WO 2006/068685 A1 (3M INNOVATIVE PROPERTIES CO [US]) 29 June 2006 (2006-06-29) page 8, line 21 - line 24 examples 1a-1d page 11, line 4 - line 5 ----- A JP 11 116633 A (CENTRAL GLASS CO LTD) 27 April 1999 (1999-04-27) examples -----	1-10 1-10 1-10



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
24 August 2012	06/09/2012

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer
--	--------------------

Behm, Sonja

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2012/031734

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 0159005	A2	16-08-2001	EP	1263857 A2	11-12-2002
			JP	2004500459 A	08-01-2004
			US	2002026014 A1	28-02-2002
			WO	0159005 A2	16-08-2001
<hr/>					
WO 2006068685	A1	29-06-2006	BR	PI0519156 A2	30-12-2008
			CA	2592041 A1	29-06-2006
			CN	101084242 A	05-12-2007
			EP	1828262 A1	05-09-2007
			JP	2008524425 A	10-07-2008
			KR	20070093083 A	17-09-2007
			US	2006135700 A1	22-06-2006
			WO	2006068685 A1	29-06-2006
<hr/>					
JP 11116633	A	27-04-1999	JP	3638076 B2	13-04-2005
			JP	11116633 A	27-04-1999
<hr/>					